Merrimack Pharmaceuticals

Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, design, and development of therapies for the treatment of diseases in the areas of autoimmunity and cancer. It develops MM-093, a human alpha-fetoprotein for the treatment of patients with rheumatoid arthritis and psoriasis; and MM-121, a human monoclonal antibody and therapeutic to block signaling of the ErbB3 receptor. Merrimack Pharmaceuticals, Inc. was formerly known as Atlantic BioPharmaceuticals, Inc. The company was founded in 1993 and is based in Cambridge, Massachusetts.